AmCham Norway’s Healthcare Working Group – comprised of directors of the leading international pharmaceutical companies in the country – works to improve Norwegian patients’ access to the most effective, innovative, and timely treatments available. The working group contributes to a wide range of healthcare policy discussions, providing policymakers and relevant stakeholders with genuine industry information and insight. This position paper summarizes the group’s positions on healthcare innovation, market access, and the pursuit of enhanced collaboration with the public sector, positions that reflect the group’s unyielding commitment to improving patient outcomes and building an improved, more sustainable healthcare system in Norway.